Targeted therapies and outcomes data: the inflammatory hypothesis matures

    loading  Checking for direct PDF access through Ovid

Excerpt

Current therapies focusing on cardiovascular disease (CVD) event prevention largely target low-density lipoprotein cholesterol (LDL-c) reduction or inhibition of platelet function. Despite the widespread use of these medication classes, CVD has remained the number one cause of death since 1911, and still accounts for approximately 30% of deaths globally [1].
    loading  Loading Related Articles